When CTI BioPharma is acquired by Swedish Orphan Biovitrum AB (Sobi), the companies intend to advance an oral kinase inhibitor treatment for a rare haematological disease.
List view / Grid view
Phase I results suggest adding pacritinib to sirolimus and low-dose tacrolimus could be beneficial in preventing graft-versus-host disease (GvHD).
15 June 2015 | By Victoria White
CTI BioPharma has announced findings from a Phase 2 trial of tosedostat in combination with low dose cytarabine in patients with acute myeloid leukaemia...